NASDAQ:AFMD Affimed (AFMD) Stock Price, News & Analysis $0.73 +0.01 (+1.03%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$0.73 0.00 (-0.61%) As of 04/17/2025 04:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Affimed Stock (NASDAQ:AFMD) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Affimed alerts:Sign Up Key Stats Today's Range$0.72▼$0.7550-Day Range$0.57▼$1.0752-Week Range$0.52▼$8.95Volume15,253 shsAverage Volume305,051 shsMarket Capitalization$11.81 millionP/E RatioN/ADividend YieldN/APrice Target$13.50Consensus RatingModerate Buy Company OverviewAffimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company's lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid. It develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. It has collaboration with Artiva Biotherapeutics to develop the combination of acimtamig and AlloNK; license and strategic collaboration agreement with Roivant Sciences Ltd. to develop and commercialize novel ICE molecules, including AFM32, in oncology; and strategic collaboration agreement with Genentech for the development of certain product candidates, which includes novel NK cell engager-based immunotherapeutics to treat multiple cancers. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Mannheim, Germany.Read More… Affimed Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks71st Percentile Overall ScoreAFMD MarketRank™: Affimed scored higher than 71% of companies evaluated by MarketBeat, and ranked 212th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingAffimed has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageAffimed has received no research coverage in the past 90 days.Read more about Affimed's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Affimed are expected to grow in the coming year, from ($4.19) to ($2.05) per share.Price to Book Value per Share RatioAffimed has a P/B Ratio of 0.18. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Affimed's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.54% of the float of Affimed has been sold short.Short Interest Ratio / Days to CoverAffimed has a short interest ratio ("days to cover") of 4.4.Change versus previous monthShort interest in Affimed has recently decreased by 1.96%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAffimed does not currently pay a dividend.Dividend GrowthAffimed does not have a long track record of dividend growth. Sustainability and ESG4.3 / 5Environmental Score-1.95 Percentage of Shares Shorted4.54% of the float of Affimed has been sold short.Short Interest Ratio / Days to CoverAffimed has a short interest ratio ("days to cover") of 4.4.Change versus previous monthShort interest in Affimed has recently decreased by 1.96%, indicating that investor sentiment is improving. News and Social Media0.6 / 5News SentimentN/A MarketBeat Follows4 people have added Affimed to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Affimed insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.80% of the stock of Affimed is held by insiders.Percentage Held by InstitutionsOnly 30.82% of the stock of Affimed is held by institutions.Read more about Affimed's insider trading history. Receive AFMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Affimed and its competitors with MarketBeat's FREE daily newsletter. Email Address AFMD Stock News HeadlinesStockNews.com Begins Coverage on Affimed (NASDAQ:AFMD)April 11, 2025 | americanbankingnews.comAffimed Announces Acceptance of AFM24 Abstract on Dose Optimization for Presentation at American Association for Cancer Research Annual MeetingMarch 25, 2025 | globenewswire.comClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code... And since then, "in the know" patriots have quietly used this same "Trump loophole" to shield their life savings from the economic chaos. But with Trump now forcefully bringing back millions of manufacturing jobs from Mexico, China, and the entire BRICS anti-dollar coalition...April 18, 2025 | American Alternative (Ad)Affimed to Present at the Leerink Partners Global Healthcare Conference 2025March 3, 2025 | globenewswire.com683 Capital Management, LLC Reduces Stake in Affimed NVFebruary 14, 2025 | gurufocus.comAnalyst revises Affimed Therapeutics stock price target amid AFM24 trial progressionDecember 20, 2024 | uk.investing.comAffimed price target lowered to $11 from $15 at Wells FargoDecember 19, 2024 | markets.businessinsider.comAffimed (AFMD) Gets a Buy from Truist FinancialDecember 19, 2024 | markets.businessinsider.comSee More Headlines AFMD Stock Analysis - Frequently Asked Questions How have AFMD shares performed this year? Affimed's stock was trading at $1.19 at the beginning of the year. Since then, AFMD shares have decreased by 38.4% and is now trading at $0.7335. View the best growth stocks for 2025 here. How were Affimed's earnings last quarter? Affimed (NASDAQ:AFMD) issued its earnings results on Wednesday, November, 10th. The biopharmaceutical company reported ($1.40) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.30) by $0.10. The biopharmaceutical company earned $10.21 million during the quarter, compared to analysts' expectations of $11.79 million. Affimed had a negative trailing twelve-month return on equity of 193.84% and a negative net margin of 7,836.26%. Read the conference call transcript. When did Affimed's stock split? Affimed shares reverse split on Monday, March 11th 2024. The 1-10 reverse split was announced on Wednesday, March 6th 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, March 8th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of Affimed? Shares of AFMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Affimed own? Based on aggregate information from My MarketBeat watchlists, some other companies that Affimed investors own include Meta Platforms (META), NVIDIA (NVDA), Novavax (NVAX), Tesla (TSLA), Advanced Micro Devices (AMD), Plug Power (PLUG) and Sorrento Therapeutics (SRNE). Company Calendar Last Earnings11/10/2021Today4/18/2025Next Earnings (Estimated)6/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AFMD CIK1608390 Webwww.affimed.com Phone496221674360Fax49-6221-653-0777Employees200Year FoundedN/APrice Target and Rating Average Stock Price Target$13.50 High Stock Price Target$25.00 Low Stock Price Target$4.00 Potential Upside/Downside+1,740.5%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-114,660,000.00 Net Margins-7,836.26% Pretax Margin-7,837.50% Return on Equity-193.84% Return on Assets-107.24% Debt Debt-to-Equity Ratio0.13 Current Ratio1.93 Quick Ratio1.93 Sales & Book Value Annual Sales$877,000.00 Price / Sales13.47 Cash FlowN/A Price / Cash FlowN/A Book Value$4.19 per share Price / Book0.18Miscellaneous Outstanding Shares16,100,000Free Float15,488,000Market Cap$11.81 million OptionableOptionable Beta2.28 Social Links 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free Report This page (NASDAQ:AFMD) was last updated on 4/18/2025 by MarketBeat.com Staff From Our PartnersElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredThe Crypto Market is About to Change LivesI've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredThey Won’t Tell You This About GoldInflation, digital currency, and government policy are quietly eating away at your savings — and most people w...American Alternative | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Affimed Please log in to your account or sign up in order to add this asset to your watchlist. Share Affimed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.